Reuters is reporting that pharmaceutical companies may be shifting the amount of taxes they owe in the United States by holding their valuable drug patents overseas.
Reuters is reporting that pharmaceutical companies may be shifting the amount of taxes they owe in the United States by holding their valuable drug patents overseas.
When the Trump administration cut the corporate tax rate to 21% from 35% with the approval of the Tax Cuts and Jobs Act, the rationale for the cut was putting a halt to outsourcing and providing an incentive for companies to keep businesses and jobs within the United States. However, drug companies like AbbVie, indicated Reuters, may be using loopholes within the law to profit from the change.
Richard Gonzalez, AbbVie’s CEO, told investors earlier this year that, due to the tax cut (which requires only profits reported by domestic subsidiaries to pay US tax), the company expects its tax rate to fall to 9% on a projected revenue of $32 billion.
Despite basing most of its research facilities in the United States, Reuters indicates that AbbVie has never recorded a profit in the United States and has reported its income in lower-tax jurisdictions, in part due to holding 88 patents for adalimumab (Humira) in Bermuda, a country that does not tax corporate profits.
In 2017, AbbVie reported $10.4 billion of foreign profits before taxes on an international revenue of $9.97 billion. Conversely, from 2013 to 2016, AbbVie reportedly paid around $1 billion a year in taxes in the United States when it took earnings reported by foreign subsidies back home to cover expenses from US-based facilities.
To avoid such profit-shifting, the government attached a provision to the Tax Cuts and Jobs Act called Global Intangible Low Tax Income (GILTI). The provision states that if a company profits from a so-called tax haven, it will be liable to have the profit taxed as income generated in the United States. However, the tax rate that applies is only half the US tax rate.
Though the exact process utilized by AbbVie to report such low tax rates is not disclosed to the public, analysts and academics within the field have noted that corporate filings often show drug companies reduce taxes by holding patents in a low or zero corporate tax country. Using this method, the affiliate companies which manufacture or market the drug pay the tax haven subsidiary royalty fees for the right to use the patent.
AbbVie is not the only pharmaceutical company benefitting from the new tax law. Amgen has reported a 14% to 15% tax rate for 2018, comparable to 17% for Pfizer and 18% for Eli Lilly.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.